Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 5,060 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
Interventions: Levetiracetam, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 35 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Depression, Suicidal Ideation
Interventions: NRX-101, Lurasidone HCl; Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Birmingham, Alabama • Hollywood, Florida • Fort Worth, Texas + 1 more

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: Ixazomib, Lenalidomide; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: West Hollywood, California

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Ezetimibe, Placebo (for Alirocumab), Placebo (for Ezetimibe); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia

Conditions: Cocaine Dependence
Interventions: Adderall-ER, Topiramate, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions: Pirfenidone Capsule, Placebo Capsule; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Myeloma
Interventions: Thalidomide, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Interventions: Bemcentinib; pembrolizumab; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Duarte, California • San Diego, California • Kansas City, Missouri + 2 more

Conditions: Breast Cancer
Interventions: Green tea extract supplement, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 1,075 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 5
States / cities: Edina, Minnesota • Maple Grove, Minnesota • Minneapolis, Minnesota + 2 more

Conditions: Advanced Cancer, Various, NOS
Interventions: BMS-833923, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 5 more

Conditions: Stress Disorders, Post-Traumatic
Interventions: Brexpiprazole, Sertraline, Brexpiprazole Matching Placebo, Sertraline Matching Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 54
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more

Conditions: Urinary Tract Infections
Interventions: Nitrofurantoin, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Endocalyx, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Chronic Myeloid Leukemia
Interventions: nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more

Conditions: Major Depressive Disorder
Interventions: saredutant (SR48968), escitalopram, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Dyslipidemia
Interventions: Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 58 more

Conditions: Dry Mouth
Interventions: Cevimeline; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Frail Elderly Syndrome
Interventions: Fisetin, Placebo oral capsule; Dietary Supplement · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 70 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteer
Interventions: Eliglustat, common blend proposed commercial formulation, Eliglustat, Phase 3 capsule formulation; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Venetoclax, Obinutuzumab, Acalabrutinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: CAH - Congenital Adrenal Hyperplasia
Interventions: NBI-74788; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: dimethyl fumarate, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 19 Years to 58 Years
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 50
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Roseville, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Early Breast Cancer
Interventions: LEE011 (ribociclib), letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Los Angeles, California • Boston, Massachusetts + 1 more

Search by objective public record fields.

Levetiracetam in Early Psychosis

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

Thalidomide-Dexamethasone for Multiple Myeloma

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Green Tea and Reduction of Breast Cancer Risk

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Nitrofurantoin and Urinary Tract Infections (UTIs)

Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)